Lung 2021 04 7;199(2):147-153. Epub 2021 Apr 7.
Department of Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd. Mail Code OP09, Portland, OR, 97239, USA.
This is a prospective, open-label, proof-of-concept study of tofacitinib, a Janus kinase inhibitor, as a steroid-sparing therapy in corticosteroid-dependent pulmonary sarcoidosis. Five patients with corticosteroid-dependent pulmonary sarcoidosis were treated with tofacitinib 5 mg twice daily. The primary endpoint was a ≥ 50% reduction in corticosteroids at week 16 with no worsening in pulmonary function or respiratory symptoms. Read More